Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men
Background:. In autoimmune bullous diseases (AIBDs), autoantibodies loosen molecular adhesions in the skin and/or mucosa and lead to blisters and erosions. Immunosuppressive drugs reduce mortality of the AIBD; therefore, patients will have to live longer with comorbidities. Objective:. This study ai...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2022-03-01
|
| Series: | International Journal of Women's Dermatology |
| Online Access: | http://journals.lww.com/10.1097/JW9.0000000000000004 |
| _version_ | 1828731414193897472 |
|---|---|
| author | Atefeh Behkar, MD, MPH Gholamreza Garmaroudi, MD, MPH, PhD Maryam Nasimi, MD, Msc Shakiba Yousefi, MD Hasan Khosravi, MD Nika Kianfar, MD Dedee F. Murrell, MD Maryam Daneshpazhooh, MD |
| author_facet | Atefeh Behkar, MD, MPH Gholamreza Garmaroudi, MD, MPH, PhD Maryam Nasimi, MD, Msc Shakiba Yousefi, MD Hasan Khosravi, MD Nika Kianfar, MD Dedee F. Murrell, MD Maryam Daneshpazhooh, MD |
| author_sort | Atefeh Behkar, MD, MPH |
| collection | DOAJ |
| description | Background:. In autoimmune bullous diseases (AIBDs), autoantibodies loosen molecular adhesions in the skin and/or mucosa and lead to blisters and erosions. Immunosuppressive drugs reduce mortality of the AIBD; therefore, patients will have to live longer with comorbidities.
Objective:. This study aims to determine the quality of life of AIBD patients undergoing systemic treatment while investigating the survey’s relationship with various factors.
Methods:. In this 2-step cross-sectional study, we initially included 53 consecutive pemphigus patients to investigate reliability and validity of the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaire. Then, we conducted the study on 119 AIBD patients, currently under treatment at an AIBD clinic in Iran.
Results:. The mean TABQOL score for our patients was 13.87 ± 7.51. The highest TABQOL was for epidermolysis bullosa acquisita (24 ± 8.485) followed by pemphigus foliaceus (20.5 ± 14.181) and the lowest for pemphigus vulgaris (13.24 ± 6.54). There was no significant difference between patients’ TABQOL scores and their gender, history of rituximab injection, and disease severity scores. We only found a positive correlation between TABQOL and prednisolone dose.
Conclusion:. Treatments of AIBD considerably impact the quality of life of patients and an impairment in quality of life is correlated to higher doses of prednisolone. |
| first_indexed | 2024-04-12T17:45:42Z |
| format | Article |
| id | doaj.art-eb95166e7bd1448496ad7180354171ba |
| institution | Directory Open Access Journal |
| issn | 2352-6475 |
| language | English |
| last_indexed | 2024-04-12T17:45:42Z |
| publishDate | 2022-03-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | International Journal of Women's Dermatology |
| spelling | doaj.art-eb95166e7bd1448496ad7180354171ba2022-12-22T03:22:41ZengWolters KluwerInternational Journal of Women's Dermatology2352-64752022-03-0181e00410.1097/JW9.0000000000000004202203000-00003Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as menAtefeh Behkar, MD, MPH0Gholamreza Garmaroudi, MD, MPH, PhD1Maryam Nasimi, MD, Msc2Shakiba Yousefi, MD3Hasan Khosravi, MD4Nika Kianfar, MD5Dedee F. Murrell, MD6Maryam Daneshpazhooh, MD7a Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iranc Department of Health Promotion & Education, Associate Professor of Maternal & Child Health, School of Public Health, Tehran University of Medical Sciences, Tehran, Irana Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iranb School of Medicine, Tehran University of Medical Sciences, Tehran, Irand Department of Dermatology, University of Illinois, Chicago, Illinoisa Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Irane Department of Dermatology at St. George Hospital, University of New South Wales, Sydney, New South Wales, Australiaa Autoimmune Bullous Disease Research Center, Razi Hospital, Department of Dermatology, Tehran University of Medical Sciences, Tehran, IranBackground:. In autoimmune bullous diseases (AIBDs), autoantibodies loosen molecular adhesions in the skin and/or mucosa and lead to blisters and erosions. Immunosuppressive drugs reduce mortality of the AIBD; therefore, patients will have to live longer with comorbidities. Objective:. This study aims to determine the quality of life of AIBD patients undergoing systemic treatment while investigating the survey’s relationship with various factors. Methods:. In this 2-step cross-sectional study, we initially included 53 consecutive pemphigus patients to investigate reliability and validity of the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaire. Then, we conducted the study on 119 AIBD patients, currently under treatment at an AIBD clinic in Iran. Results:. The mean TABQOL score for our patients was 13.87 ± 7.51. The highest TABQOL was for epidermolysis bullosa acquisita (24 ± 8.485) followed by pemphigus foliaceus (20.5 ± 14.181) and the lowest for pemphigus vulgaris (13.24 ± 6.54). There was no significant difference between patients’ TABQOL scores and their gender, history of rituximab injection, and disease severity scores. We only found a positive correlation between TABQOL and prednisolone dose. Conclusion:. Treatments of AIBD considerably impact the quality of life of patients and an impairment in quality of life is correlated to higher doses of prednisolone.http://journals.lww.com/10.1097/JW9.0000000000000004 |
| spellingShingle | Atefeh Behkar, MD, MPH Gholamreza Garmaroudi, MD, MPH, PhD Maryam Nasimi, MD, Msc Shakiba Yousefi, MD Hasan Khosravi, MD Nika Kianfar, MD Dedee F. Murrell, MD Maryam Daneshpazhooh, MD Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men International Journal of Women's Dermatology |
| title | Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men |
| title_full | Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men |
| title_fullStr | Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men |
| title_full_unstemmed | Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men |
| title_short | Assessing quality of life in patients with autoimmune bullous diseases using the Persian version of Treatment of Autoimmune Bullous Disease Quality of Life questionnaire finds similar effects in women as men |
| title_sort | assessing quality of life in patients with autoimmune bullous diseases using the persian version of treatment of autoimmune bullous disease quality of life questionnaire finds similar effects in women as men |
| url | http://journals.lww.com/10.1097/JW9.0000000000000004 |
| work_keys_str_mv | AT atefehbehkarmdmph assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen AT gholamrezagarmaroudimdmphphd assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen AT maryamnasimimdmsc assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen AT shakibayousefimd assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen AT hasankhosravimd assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen AT nikakianfarmd assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen AT dedeefmurrellmd assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen AT maryamdaneshpazhoohmd assessingqualityoflifeinpatientswithautoimmunebullousdiseasesusingthepersianversionoftreatmentofautoimmunebullousdiseasequalityoflifequestionnairefindssimilareffectsinwomenasmen |